Aug. 20, 2024 – The weight loss and diabetes drug tirzepatide, sold under the brand name Zepbound, was highly effective at reducing the risk of progressing from prediabetes to the more serious condition of type 2 diabetes, according to a glimpse of early study results released Tuesday by drugmaker Eli Lilly.Tirzepatide is sold under the brand name Zepbound for weight loss and under the name Mounjaro for diabetes.

2024年8月20日——根据制药商礼来公司（Eli Lilly）周二发布的早期研究结果，以Zepbound品牌销售的减肥和糖尿病药物替罗帕肽在降低糖尿病前期发展为更严重的2型糖尿病的风险方面非常有效。替西帕肽以减肥药Zepbound和糖尿病药Mounjaro的名义销售。

The medicine works like other well-known diabetes and weight loss drugs like Ozempic and Wegovy. Tirzepatide is known as a dual GLP-1/GIP receptor agonist, meaning it works in two ways to mimic hormones released in the gut that can affect appetite and caloric intake. It can also impact insulin production.These latest results are from a phase III clinical trial of tirzepatide, which is usually the largest phase of examining a drug’s effects and safety.

该药与其他著名的糖尿病和减肥药（如Ozempic和Wegovy）一样有效。Tirzepatide被称为双重GLP-1/GIP受体激动剂，这意味着它可以通过两种方式模拟肠道释放的激素，从而影响食欲和热量摄入。它也会影响胰岛素的产生。这些最新结果来自替罗西肽的III期临床试验，这通常是检查药物效果和安全性的最大阶段。

Called the SURMOUNT-1 trial, this new analysis included 1,032 adults who had prediabetes and overweight or obesity. Results were compared among people who took a placebo, or one of three dosages of tirzepatide (5 milligrams, 10 milligrams, or 15 milligrams) that were given weekly as a shot for 176 weeks, which is more than 3 years.

这项新的分析被称为Overside-1试验，包括1032名患有糖尿病前期和超重或肥胖的成年人。结果在服用安慰剂或三剂（5毫克、10毫克或15毫克）的人中进行了比较，这些人每周服用176周，即3年以上。

The people taking tirzepatide had up to a 94% reduced risk of progression to type 2 diabetes, Eli Lilly announced in a news release. The announcement was posted on Eli Lilly’s website for investors as part of rules that drug companies must follow regarding clinical trial information. These latest results will be presented at the ObesityWeek 2024 medical conference in November and submitted to a peer-reviewed professional journal, the company said in the release.Study results also showed a notable average weight loss ranging from 15% to 23% of body weight, depending on dosage, compared t.

礼来公司（EliLilly）在一份新闻稿中宣布，服用tirzepatide的人进展为2型糖尿病的风险降低了94%。该公告发布在礼来公司的投资者网站上，作为制药公司在临床试验信息方面必须遵守的规则的一部分。该公司在新闻稿中表示，这些最新结果将在11月的ObesityWeek 2024医学会议上公布，并提交给同行评审的专业期刊。研究结果还显示，与t相比，根据剂量的不同，显着的平均体重减轻范围为体重的15%至23%。